89bio Inc Stock, NASDAQ:ETNB
89bio, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of innovative therapies for nonalcoholic steatohepatitis (NASH), liver and cardio-metabolic diseases. The firm product candidates and pipeline include BIO89-100, FGF21, NASH, and SHTG. The company was founded on January 01, 2018 and is headquartered in San Francisco, CA.